An immunohistochemical study of the acute and long-term effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in the marmoset

Neuroscience

Volumn 23, Issue 3, 1987, Pages 1025-1039

  Waters, C M ^a   Hunt, S P ^a   Jenner, P ^b   Marsden, C D ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Institute of Neurology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTOXIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CYTOCHEMISTRY; HISTOCHEMISTRY; IMMUNOCYTOCHEMISTRY; MARMOSET; MONKEY; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMAL; CALLITRICHINAE; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; NEUROPEPTIDES; PARKINSON DISEASE, SECONDARY; PYRIDINES; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 0023550354     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(87)90178-3     Document Type: Article

References (75)

1. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
2. Permanent human Parkinsonism due to 1-methyl-4-pnenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases
3. The use of L-DOPA in Parkinson's disease: a 20 year follow-up
4. Dopamine-containing systems in the CNS
5. A morphometric study of the dopamine containing cell groups in the mesencephalon of normal, Parkinson patients and schizophrenics
6. A primate model of Parkinsonism: selective destruction of dopaminergic neurones in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
7. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease
8. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
9. Failure of SKF 38393-A to relieve Parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys
10. Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP)
11. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
12. + binds to neuromelanin
13. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues
14. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains
15. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
16. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonism in monkeys
17. Regional distribution of methionine enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease
18. Short- and long-term changes in adrenal tyrosine hydroxylase activity during insulin-induced hypoglycemia and cold stress
19. Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man
20. Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases
21. THE BRAIN-STEM LESIONS IN PARKINSONISM
22. The distribution of enkephalin immunoreactive fibres and terminals in the monkey central nervous system: an immunohistochemical study
23. The comparison between enkephalin-like and dynorphin-like immunoreactivity in both monkey and human globus pallidus and substantia nigra
24. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monamine oxidase, MPTP metabolism and neurotoxicity
25. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
26. 3H]5-hydroxytryptamine in neostriatal synaptosomal preparations
27. Distribution of substance P and enkephalin-like immunoreactivity in the substantia nigra of rat, cat and monkey
28. Longterm regulation of tyrosine hydroxylase activity in the superior cervical ganglion in organ culture: effects of nerve stimulation and dexamethasone
29. N-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey
30. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
31. Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects
32. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinsonian in the common marmoset
33. Evidence for a decrease in substance P content of substantia nigra in Huntingdon's chorea
34. Electrophysiological evidence for the excitatory fibres in the caudato-nigral pathway in the cat
35. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A tyrosine hydroxylase immunocytochemical study in monkey
36. Two distinct striato-nigral substance P pathways in the rat: an experimental immunocytochemical study
37. Methods for counting of neurons
38. Ultrastructural evidence of dopaminergic input to enkephalinergic neurons in rat neostriatum
39. MPTP neurotoxicity: an overview and characterisation of phases of neurotoxicity
40. Chronic Parkinsonian in humans due to a product of meperidine-analog synthesis
41. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey
42. Pargyline prevents MPTP-induced Parkinsonism in primates
43. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonin containing cells
44. Paralysis agitans, I. Pathologische Anatomie
45. Enkephalinergic markers in substantia nigra and caudate nucleus from Parkinsonian subjects
46. Intraneuronal generation of a pyridinium metabolite may cause drug induced Parkinsonism
47. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains
48. Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens
49. N-methyl-4-phenyl-1,2,3,6-tetrahydrapyridine (MPTP) causes destruction of the mesolimbic dopamine system and the locus coeruleus in the primate
50. Brain glutamate decar☐ylase in Parkinson's disease with particular reference to a premortem severity index
51. Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P
52. Immunocytochemical studies of gabaergic neurones in rat basal ganglia and their relations to other neuronal systems
53. The number of nerve cells in the substantia nigra in Paralysis Agitans
54. On the origin of dynorphin A and α-neo-endorphin in the substantia nigra
55. The subcortical afferents to caudate nucleus and putamen in primate: a fluorescence retrograde double labelling study
56. Human brainstem catecholamine neuronal anatomy as indicated by immunocytochemistry with antibodies to tyrosine hydroxylase
57. The glutamate decar☐ylase-, leucine enkephalin- and substance P-immunoreactive neurons in the neostriatum of the rat and cat: evidence for partial population overlap
58. Specificity of antisera prepared against pure bovine MAO-B
59. Loss of substance P and enkephalin immunoreactivity in the human substantia nigra after striato-pallidal infarction
60. Possible interaction between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra
61. Cell type specific markers for distinguishing and studying the major classes of glial cells in culture
62. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monomine oxidases A and B and suicide inactivation of the enzymes by MPTP
63. Opposite responses in the striato-nigral substance P system to D-1 and D-2 receptor activation
64. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat
65. 5-enkephalin production from either pro-enkephalin A or prodynorphin in human brain
66. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-pheaypyridmium
67. A comparison of neurochemical changes seen in MPTP treatment of the common marmoset with those occurring in Parkinson's disease
68. Neuropathological, immunohistochemical and receptor changes seen in marmosets treated with MPTP
69. Distinct monoamine oxidase A and B populations in primate brain
70. Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia
71. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical Parkinsonism